Annuncio • Jan 16
Neurogene Announces Appointment of Julie Jordan, M.D., as Chief Medical Officer Neoleukin Therapeutics, Inc. announced the appointment of Julie Jordan, M.D., as Chief Medical Officer. Dr. Jordan brings to Neurogene over 20 years of industry and clinical expertise involving the design and execution of global clinical trials across multiple development areas, including gene therapy and central nervous system disorders. She most recently served as Chief Medical Officer of Homology Medicines, a clinical-stage company advancing gene therapies for the treatment of rare diseases. In her prior role as Chief Medical Officer of Homology Medicines, Dr. Jordan was responsible for leading clinical development and operations, leading regulatory interactions and supporting translational research programs for the company’s pipeline of gene therapy and gene editing candidates for rare diseases. Prior to assuming her role as Chief Medical Officer, Dr. Jordan served as the company’s Senior Vice President, Head of Clinical Development and Operations. During her tenure, she successfully drove development and navigated regulatory challenges for multiple first-in-class genetic medicines, built and led a team of functional experts across multiple disciplines, and played a key role in strengthening relationships with patient advocacy groups and key opinion leaders. Before joining Homology Medicines, she held global leadership roles of increasing responsibility for central nervous system, neuropsychiatry, and other programs at Cerevel Therapeutics, Avanir Pharmaceuticals and Teva Pharmaceutical Industries. Before joining industry, Dr. Jordan was a practicing physician for 10 years and previously served as Clinical Instructor of Medicine at Harvard Medical School and in the Department of Medicine at Massachusetts General Hospital (MGH). She holds an A.B. in Biology from Harvard College and an M.D. from Harvard Medical School and completed her residency in Internal Medicine at MGH, Harvard Medical School. Annuncio • Sep 23
Neoleukin Therapeutics Announces 1-for-5 Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price Requirement Neoleukin Therapeutics, Inc. announced that its board of directors (‘Board’) has approved a reverse stock split of the company’s outstanding shares of common stock at a ratio of 1-for-5. The reverse stock split will become effective at 12:01 a.m. Eastern time on September 25, 2023. Neoleukin’s common stock will begin trading on a post-reverse stock split basis on September 25, 2023, under Neoleukin’s existing trading symbol ‘NLTX’ with a new CUSIP number 64049K203. The reverse stock split is part of Neoleukin’s plan to regain compliance with Nasdaq’s minimum bid price requirement of $1.00 per share. The reverse stock split was approved by Neoleukin’s stockholders at the Company’s 2023 Annual Meeting of Stockholders held on June 8, 2023, to be effected in the Board’s discretion within approved parameters. New Risk • Jul 21
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.6% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 7.3% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (3.6% increase in shares outstanding). Market cap is less than US$100m (US$29.5m market cap). Board Change • Nov 16
High number of new and inexperienced directors There are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. 3 experienced directors. 1 highly experienced director. Independent Chairman Todd Simpson is the most experienced director on the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Annuncio • Nov 01
Neoleukin Therapeutics Receives Notice from the Nasdaq Stock Market LLC for Minimum Bid Price Requirement On October 26, 2022, Neoleukin Therapeutics, Inc. (the ‘Company’) received notice (the ‘Notice’) from the Listing Qualifications staff of the Nasdaq Stock Market LLC (‘Nasdaq’) that, because the closing bid price for the Company's common stock has fallen below $1.00 per share for 30 consecutive business days, the Company no longer complies with the minimum bid price requirement for continued listing on the Nasdaq Global Market under Nasdaq Listing Rule 5550(a)(2). The Notice has no immediate effect on the listing of the Company's common stock on the Nasdaq Global Market. Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial compliance period of 180 calendar days, or until April 24, 2023, to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Company's common stock must meet or exceed $1.00 per share for a minimum of 10 consecutive business days prior to April 24, 2023. If the Company does not regain compliance by April 24, 2023, the Company may be eligible for an additional 180 calendar day grace period if it applies to transfer the listing of its common stock to the Nasdaq Capital Market. To qualify, the Company would be required to meet the continued listing requirement for the market value of its publicly held shares and all other initial listing standards for the Nasdaq Global Market, with the exception of the minimum bid price requirement, and provide written notice of its intention to cure the minimum bid price deficiency during the second compliance period by effecting a reverse stock split, if necessary. If the Nasdaq staff determines that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible for such additional compliance period, Nasdaq will provide notice that the Company's common stock will be subject to delisting. The Company would have the right to appeal a determination to delist its common stock, and the common stock would remain listed on the Nasdaq Global Market until the completion of the appeal process. The Company is considering actions that it may take in response to this Notice in order to regain compliance with the continued listing requirements, but no decisions about a response have been made at this time. There can be no assurance that the Company will be able to regain compliance with the minimum bid price requirement or will otherwise be in compliance with other Nasdaq listing criteria. Price Target Changed • Sep 12
Price target decreased to US$10.50 Down from US$13.14, the current price target is an average from 6 analysts. New target price is 881% above last closing price of US$1.07. Stock is down 86% over the past year. The company is forecast to post a net loss per share of US$1.20 next year compared to a net loss per share of US$1.10 last year. Price Target Changed • Aug 12
Price target decreased to US$11.71 Down from US$13.14, the current price target is an average from 6 analysts. New target price is 893% above last closing price of US$1.18. Stock is down 83% over the past year. The company is forecast to post a net loss per share of US$1.20 next year compared to a net loss per share of US$1.10 last year. Annuncio • Jul 28
Neoleukin Therapeutics, Inc. to Report Q2, 2022 Results on Aug 09, 2022 Neoleukin Therapeutics, Inc. announced that they will report Q2, 2022 results at 4:00 PM, US Eastern Standard Time on Aug 09, 2022 Price Target Changed • Jul 06
Price target decreased to US$13.14 Down from US$15.00, the current price target is an average from 5 analysts. New target price is 1,201% above last closing price of US$1.01. Stock is down 89% over the past year. The company is forecast to post a net loss per share of US$1.23 next year compared to a net loss per share of US$1.10 last year. Annuncio • Jun 26
Neoleukin Therapeutics, Inc.(NasdaqGM:NLTX) dropped from Russell 2000 Dynamic Index Neoleukin Therapeutics, Inc.(NasdaqGM:NLTX) dropped from Russell 2000 Dynamic Index Price Target Changed • May 30
Price target decreased to US$15.00 Down from US$18.29, the current price target is an average from 6 analysts. New target price is 1,400% above last closing price of US$1.00. Stock is down 90% over the past year. The company is forecast to post a net loss per share of US$1.23 next year compared to a net loss per share of US$1.10 last year. Annuncio • May 18
Neoleukin Therapeutics, Inc. Announces First Patient Treated in Combination Arm of Phase 1 Trial Evaluating Nl-201 in Combination with Keytruda® (Pembrolizumab) Neoleukin Therapeutics, Inc. announced treatment of the first patient in a combination arm evaluating the safety and efficacy of Neoleukin’s NL-201 in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab), as part of Neoleukin’s ongoing Phase 1 trial in patients with relapsed or refractory solid tumors. Up to 132 patients will be enrolled in the combination arm of the study, which is being conducted through a clinical collaboration and supply agreement with Merck (known as MSD outside the United States and Canada). The trial is assessing safety, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity. KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. Annuncio • May 10
Neoleukin Therapeutics, Inc. Provides NL-201 Update Neoleukin Therapeutics, Inc. provided NL-201 Update. Neoleukin is conducting a clinical trial of intravenous NL-201 in patients with advanced solid tumors. It is currently enrolling patients at sites in Australia, the United States, and Canada, evaluating two different schedules and multiple dose levels in order to determine a recommended Phase 2 dose and schedule. Neoleukin anticipates disclosing interim data during the second half of 2022. Based on encouraging preclinical activity, Neoleukin announced plans to initiate a separate clinical trial to evaluate NL-201 in patients with hematologic malignancies. The timing for enrolling patients in this trial will be determined based on data the company receive from the company's ongoing solid tumor Phase 1 trial relating to safety and optimal dosing schedules. Price Target Changed • Apr 27
Price target decreased to US$18.29 Down from US$19.71, the current price target is an average from 6 analysts. New target price is 1,363% above last closing price of US$1.25. Stock is down 90% over the past year. The company is forecast to post a net loss per share of US$1.24 next year compared to a net loss per share of US$1.10 last year. Board Change • Apr 27
High number of new and inexperienced directors There are 11 new directors who have joined the board in the last 3 years. The company's board is composed of: 11 new directors. No experienced directors. 1 highly experienced director. Independent Chairman Todd Simpson is the most experienced director on the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Annuncio • Apr 01
Neoleukin Therapeutics, Inc., Annual General Meeting, May 12, 2022 Neoleukin Therapeutics, Inc., Annual General Meeting, May 12, 2022, at 13:30 Pacific Standard Time. Agenda: To elect Jonathan G. Drachman and Sarah B. Noonberg as class ii directors of the company to hold office until the 2025 annual meeting of stockholders; to ratify the appointment of deloitte & touche llp as the independent registered public accounting firm of the company for its fiscal year ending December 31, 2022; to approve, by a non-binding advisory vote, the compensation paid by the company to its named executive officers; and to conduct any other business properly brought before the meeting. Price Target Changed • Mar 22
Price target decreased to US$18.29 Down from US$19.71, the current price target is an average from 6 analysts. New target price is 847% above last closing price of US$1.93. Stock is down 84% over the past year. The company is forecast to post a net loss per share of US$1.24 next year compared to a net loss per share of US$1.10 last year. Annuncio • Mar 03
Neoleukin Therapeutics Inc. Announces Executive Changes Neoleukin Therapeutics Inc. announced the appointment of Rohan Palekar, Chief Executive Officer of 89bio, Inc, to Neoleukin's Board of Directors, and the departure of Lewis Rusty Williams, MD, PhD, from the board. Mr. Palekar has served as the CEO of 89bio since June 2018. Price Target Changed • Mar 03
Price target decreased to US$19.71 Down from US$21.57, the current price target is an average from 6 analysts. New target price is 625% above last closing price of US$2.72. Stock is down 77% over the past year. Annuncio • Feb 24
Neoleukin Therapeutics, Inc. to Report Fiscal Year 2021 Results on Mar 01, 2022 Neoleukin Therapeutics, Inc. announced that they will report fiscal year 2021 results After-Market on Mar 01, 2022 Annuncio • Jan 12
Neoleukin Therapeutics Announces Clinical Collaboration with Merck to Evaluate NL-201 in Combination with KEYTRUDA® (pembrolizumab) Neoleukin Therapeutics, Inc. announced a clinical trial collaboration and supply agreement with Merck (known as MSD outside the United States and Canada). The agreement will allow for the evaluation of safety and efficacy of Neoleukin’s NL-201, a de novo protein designed to mimic the therapeutic activity of natural cytokines IL-2 and IL-15, in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in an ongoing Phase 1 trial. Neoleukin will evaluate NL-201 plus pembrolizumab as part of the company’s ongoing Phase 1 trial in patients with advanced, relapsed or refractory solid tumors. Up to 132 patients will be enrolled in the combination arm of the study. The trial is assessing safety, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity. Annuncio • Dec 12
Neoleukin Therapeutics Announces Preclinical Data Highlighting Activity of NL-201 in Hematologic Malignancies At American Society of Hematology Annual Meeting Neoleukin Therapeutics, Inc. announced the presentation of preclinical data on NL-201 in multiple myeloma at the 63rdAmerican Society of Hematology (ASH) Annual Meeting and Exposition taking place virtually and in person December 11-14, 2021. Additionally, a published abstract in Blood reports on NL-201 antitumor activity in preclinical studies of non-Hodgkin lymphoma. NL-201 is a de novo agonist of the IL-2 and IL-15 receptors, designed to expand cancer-fighting CD8 T cells and natural killer (NK) cells without a bias toward cells expressing the IL-2 receptor alpha subunit (CD25). NL-201 is currently in a Phase 1 clinical trial for patients with solid tumors. Executive Departure • Nov 29
General Counsel & Secretary Holly Vance has left the company On the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after less than a year in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Nov 29
General Counsel & Secretary Holly Vance has left the company On the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after less than a year in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Nov 29
General Counsel & Secretary Holly Vance has left the company On the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after less than a year in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Nov 29
General Counsel & Secretary Holly Vance has left the company On the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after less than a year in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Nov 28
General Counsel & Secretary Holly Vance has left the company On the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after less than a year in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Nov 28
General Counsel & Secretary Holly Vance has left the company On the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after less than a year in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Nov 28
General Counsel & Secretary Holly Vance has left the company On the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after less than a year in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Nov 28
General Counsel & Secretary Holly Vance has left the company On the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after less than a year in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Nov 28
General Counsel & Secretary Holly Vance has left the company On the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after less than a year in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Nov 28
General Counsel & Secretary Holly Vance has left the company On the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after less than a year in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Nov 28
General Counsel & Secretary Holly Vance has left the company On the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after less than a year in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Nov 27
General Counsel & Secretary Holly Vance has left the company On the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after less than a year in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Nov 27
General Counsel & Secretary Holly Vance has left the company On the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after less than a year in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Nov 27
General Counsel & Secretary Holly Vance has left the company On the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after less than a year in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Nov 27
General Counsel & Secretary Holly Vance has left the company On the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after less than a year in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Nov 27
General Counsel & Secretary Holly Vance has left the company On the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after less than a year in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Nov 27
General Counsel & Secretary Holly Vance has left the company On the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after less than a year in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Nov 27
General Counsel & Secretary Holly Vance has left the company On the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after less than a year in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Nov 27
General Counsel & Secretary Holly Vance has left the company On the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Nov 27
General Counsel & Secretary Holly Vance has left the company On the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Nov 27
General Counsel & Secretary Holly Vance has left the company On the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Nov 27
General Counsel & Secretary Holly Vance has left the company On the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Nov 26
General Counsel & Secretary Holly Vance has left the company On the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Nov 26
General Counsel & Secretary Holly Vance has left the company On the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Nov 26
General Counsel & Secretary Holly Vance has left the company On the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Nov 26
General Counsel & Secretary Holly Vance has left the company On the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Nov 26
General Counsel & Secretary Holly Vance has left the company On the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Nov 26
General Counsel & Secretary Holly Vance has left the company On the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Nov 26
General Counsel & Secretary Holly Vance has left the company On the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Nov 26
General Counsel & Secretary Holly Vance has left the company On the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Nov 26
General Counsel & Secretary Holly Vance has left the company On the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Nov 26
General Counsel & Secretary Holly Vance has left the company On the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Nov 26
General Counsel & Secretary Holly Vance has left the company On the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Nov 26
General Counsel & Secretary Holly Vance has left the company On the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Nov 26
General Counsel & Secretary Holly Vance has left the company On the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Nov 26
General Counsel & Secretary Holly Vance has left the company On the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Nov 25
General Counsel & Secretary Holly Vance has left the company On the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Nov 25
General Counsel & Secretary Holly Vance has left the company On the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Nov 25
General Counsel & Secretary Holly Vance has left the company On the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Nov 25
General Counsel & Secretary Holly Vance has left the company On the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Nov 25
General Counsel & Secretary Holly Vance has left the company On the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Nov 25
General Counsel & Secretary Holly Vance has left the company On the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Nov 25
General Counsel & Secretary Holly Vance has left the company On the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Nov 25
General Counsel & Secretary Holly Vance has left the company On the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Nov 25
General Counsel & Secretary Holly Vance has left the company On the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Nov 25
General Counsel & Secretary Holly Vance has left the company On the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Nov 25
General Counsel & Secretary Holly Vance has left the company On the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Nov 25
General Counsel & Secretary Holly Vance has left the company On the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Nov 25
General Counsel & Secretary Holly Vance has left the company On the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Nov 25
General Counsel & Secretary Holly Vance has left the company On the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Nov 25
General Counsel & Secretary Holly Vance has left the company On the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Nov 25
General Counsel & Secretary Holly Vance has left the company On the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Nov 25
General Counsel & Secretary Holly Vance has left the company On the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Nov 25
General Counsel & Secretary Holly Vance has left the company On the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Nov 25
General Counsel & Secretary Holly Vance has left the company On the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Nov 25
General Counsel & Secretary Holly Vance has left the company On the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Nov 25
General Counsel & Secretary Holly Vance has left the company On the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Nov 25
General Counsel & Secretary Holly Vance has left the company On the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Nov 24
General Counsel & Secretary Holly Vance has left the company On the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Nov 24
General Counsel & Secretary Holly Vance has left the company On the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Nov 24
General Counsel & Secretary Holly Vance has left the company On the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.